{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T03:50:16Z","timestamp":1776916216861,"version":"3.51.2"},"publisher-location":"Berlin, Heidelberg","reference-count":98,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/82_2025_308","type":"book-chapter","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T06:52:23Z","timestamp":1749192743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prophylactic and Therapeutic EBV Vaccination"],"prefix":"10.1007","author":[{"given":"Rajiv","family":"Khanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey I.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"issue":"Pt 1","key":"308_CR1","first-page":"365","volume":"390","author":"A Ascherio","year":"2015","unstructured":"Ascherio A, Munger KL (2015) EBV and autoimmunity. Curr Top Microbiol Immunol 390(Pt 1):365\u2013385","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"308_CR2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jis646","volume":"207","author":"HH Balfour Jr","year":"2013","unstructured":"Balfour HH Jr, Odumade OA, Schmeling DO et al (2013) Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis 207(1):80\u201388","journal-title":"J Infect Dis"},{"issue":"2","key":"308_CR3","volume":"4","author":"HH Balfour Jr","year":"2015","unstructured":"Balfour HH Jr, Dunmire SK, Hogquist KA (2015) Infectious mononucleosis. Clin Transl Immunol 4(2):e33","journal-title":"Clin Transl Immunol"},{"issue":"2","key":"308_CR4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bjh.19255","volume":"204","author":"K Bednarska","year":"2024","unstructured":"Bednarska K, Chowdhury R, Tobin JWD et al (2024) Epstein-Barr virus-associated lymphomas decoded. Br J Haematol 204(2):415\u2013433","journal-title":"Br J Haematol"},{"issue":"5","key":"308_CR5","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","volume":"50","author":"W Bu","year":"2019","unstructured":"Bu W, Joyce MG, Nguyen H, Banh DV, Aguilar F, Tariq Z, Yap ML, Tsujimura Y, Gillespie RA, Tsybovsky Y, Andrews SF, Narpala SR, McDermott AB, Rossmann MG, Yasutomi Y, Nabel GJ, Kanekiyo M, Cohen JI (2019) Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein-Barr virus in B cells and epithelial cells. Immunity 50(5):1305\u20131316.e6","journal-title":"Immunity"},{"issue":"8","key":"308_CR6","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/nm0896-906","volume":"2","author":"MF Callan","year":"1996","unstructured":"Callan MF, Steven N, Krausa P et al (1996) Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med 2(8):906\u2013911","journal-title":"Nat Med"},{"key":"308_CR7","doi-asserted-by":"crossref","first-page":"20464","DOI":"10.1073\/pnas.0907508106","volume":"106","author":"LS Chesnokova","year":"2009","unstructured":"Chesnokova LS, Nishimura SL, Hutt-Fletcher LM (2009) Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8. Proc Natl Acad Sci USA 106:20464\u201320469","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"308_CR8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/annonc\/mdr341","volume":"23","author":"WK Chia","year":"2012","unstructured":"Chia WK, Wang WW, Teo M et al (2012) A phase II study evaluating the safety and efficacy of an adenovirus-DeltaLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol 23(4):997\u20131005","journal-title":"Ann Oncol"},{"issue":"1","key":"308_CR9","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2014.27","volume":"4","author":"JI Cohen","year":"2015","unstructured":"Cohen JI (2015) Epstein-Barr virus vaccines. Clin Transl Immunol 4(1):e32","journal-title":"Clin Transl Immunol"},{"issue":"4","key":"308_CR10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1128\/CVI.00674-15","volume":"23","author":"JI Cohen","year":"2016","unstructured":"Cohen JI (2016) Epstein-Barr virus vaccines. Clin Vaccine Immunol 23(4):363\u2013369","journal-title":"Clin Vaccine Immunol"},{"issue":"107","key":"308_CR11","doi-asserted-by":"crossref","first-page":"107fs107","DOI":"10.1126\/scitranslmed.3002878","volume":"3","author":"JI Cohen","year":"2011","unstructured":"Cohen JI, Fauci AS, Varmus H et al (2011) Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med 3(107):107fs107","journal-title":"Sci Transl Med"},{"issue":"30","key":"308_CR12","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1016\/j.vaccine.2013.04.071","volume":"31","author":"X Cui","year":"2013","unstructured":"Cui X, Cao Z, Sen G, Chattopadhyay G, Fuller DH, Fuller JT, Snapper DM, Snow AL, Mond JJ, Snapper CM (2013) A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine. Vaccine 31(30):3039\u20133045","journal-title":"Vaccine"},{"issue":"34","key":"308_CR13","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","volume":"34","author":"X Cui","year":"2016","unstructured":"Cui X, Cao Z, Chen Q, Arjunaraja S, Snow AL, Snapper CM (2016) Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. Vaccine 34(34):4050\u20134055","journal-title":"Vaccine"},{"issue":"3","key":"308_CR14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/vaccines9030285","volume":"9","author":"X Cui","year":"2021","unstructured":"Cui X, Cao Z, Ishikawa Y, Cui S, Imadome KI, Snapper CM (2021) Immunization with Epstein-Barr Virus Core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose EBV challenge. Vaccines (Basel) 9(3):285","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"308_CR15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/14760584.2017.1293529","volume":"16","author":"V Dasari","year":"2017","unstructured":"Dasari V, Bhatt KH, Smith C et al (2017) Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities. Expert Rev Vaccines 16(4):377\u2013390","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"308_CR16","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1038\/s41467-023-39770-1","volume":"14","author":"V Dasari","year":"2023","unstructured":"Dasari V, McNeil LK, Beckett K et al (2023) Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice. Nat Commun 14(1):4371","journal-title":"Nat Commun"},{"key":"308_CR17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.coi.2018.06.002","volume":"54","author":"H de Buhr","year":"2018","unstructured":"de Buhr H, Lebbink RJ (2018) Harnessing CRISPR to combat human viral infections. Curr Opin Immunol 54:123\u2013129","journal-title":"Curr Opin Immunol"},{"key":"308_CR18","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/370516","volume":"2012","author":"AH Draborg","year":"2012","unstructured":"Draborg AH, Duus K, Houen G (2012) Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol 2012:370516","journal-title":"Clin Dev Immunol"},{"key":"308_CR19","first-page":"5","volume":"5","author":"J Duraiswamy","year":"2003","unstructured":"Duraiswamy J, Sherritt M, Thomson S et al (2003) Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin\u2019s disease and nasopharyngeal carcinoma. Blood 5:5","journal-title":"Blood"},{"issue":"4","key":"308_CR20","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1158\/0008-5472.CAN-03-2196","volume":"64","author":"J Duraiswamy","year":"2004","unstructured":"Duraiswamy J, Bharadwaj M, Tellam J et al (2004) Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res 64(4):1483\u20131489","journal-title":"Cancer Res"},{"issue":"1","key":"308_CR21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41541-024-00907-y","volume":"9","author":"KR Edwards","year":"2024","unstructured":"Edwards KR, Malhi H, Schmidt K, Davis AR, Homad LJ, Warner NL, Chhan CB, Scharffenberger SC, Gaffney K, Hinkley T, Potchen NB, Wang JY, Price J, McElrath MJ, Olson J, King NP, Lund JM, Moodie Z, Erasmus JH, McGuire AT (2024a) A gH\/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge. NPJ Vaccines 9(1):120","journal-title":"NPJ Vaccines"},{"issue":"6","key":"308_CR22","volume":"5","author":"KR Edwards","year":"2024","unstructured":"Edwards KR, Schmidt K, Homad LJ, Kher GM, Xu G, Rodrigues KA, Ben-Akiva E, Abbott J, Prlic M, Newell EW, De Rosa SC, Irvine DJ, Pancera M, McGuire AT (2024b) Vaccination with nanoparticles displaying gH\/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus. Cell Rep Med. 5(6):101587","journal-title":"Cell Rep Med."},{"issue":"3","key":"308_CR23","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/JVI.01409-07","volume":"82","author":"SL Elliott","year":"2008","unstructured":"Elliott SL, Suhrbier A, Miles JJ et al (2008) Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 82(3):1448\u20131457","journal-title":"J Virol"},{"issue":"7327","key":"308_CR24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0140-6736(64)92354-2","volume":"1","author":"MA Epstein","year":"1964","unstructured":"Epstein MA, Barr YM (1964) Cultivation in vitro of human lymphoblasts from Burkitt\u2019s malignant lymphoma. Lancet 1(7327):252\u2013253","journal-title":"Lancet"},{"issue":"7335","key":"308_CR25","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","volume":"1","author":"MA Epstein","year":"1964","unstructured":"Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma. Lancet 1(7335):702\u2013703","journal-title":"Lancet"},{"key":"308_CR26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1084\/jem.121.5.761","volume":"121","author":"MA Epstein","year":"1965","unstructured":"Epstein MA, Henle G, Achong BG et al (1965) Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt\u2019s lymphoma. J Exp Med 121:761\u2013770","journal-title":"J Exp Med"},{"issue":"6043","key":"308_CR27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/318287a0","volume":"318","author":"MA Epstein","year":"1985","unstructured":"Epstein MA, Morgan AJ, Finerty S, Randle BJ, Kirkwood JK (1985) Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 318(6043):287\u2013289","journal-title":"Nature"},{"issue":"2","key":"308_CR28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3390\/vaccines8020169","volume":"8","author":"GM Escalante","year":"2020","unstructured":"Escalante GM, Foley J, Mutsvunguma LZ, Rodriguez E, Mulama DH, Muniraju M, Ye P, Barasa AK, Ogembo JG (2020) A pentavalent Epstein-Barr Virus-like particle vaccine elicits high titers of neutralizing antibodies against Epstein-Barr Virus infection in immunized rabbits. Vaccines (Basel) 8(2):169","journal-title":"Vaccines (Basel)"},{"key":"308_CR29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867918","volume":"13","author":"GM Escalante","year":"2022","unstructured":"Escalante GM, Mutsvunguma LZ, Muniraju M et al (2022) Four decades of prophylactic EBV vaccine research: a systematic review and historical perspective. Front Immunol 13:867918","journal-title":"Front Immunol"},{"key":"308_CR30","doi-asserted-by":"crossref","first-page":"1445209","DOI":"10.3389\/fimmu.2024.1445209","volume":"15","author":"GM Escalante","year":"2024","unstructured":"Escalante GM, Reidel IG, Mutsvunguma LZ, Cua S, Tello BA, Rodriguez E, Farelo MA, Zimmerman C, Muniraju M, Li H, Govindan AN, Axthelm MK, Wong SW, Ogembo JG (2024) Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice. Front Immunol 15:1445209","journal-title":"Front Immunol"},{"key":"308_CR31","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1073\/pnas.81.14.4510","volume":"81","author":"JD Fingeroth","year":"1984","unstructured":"Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT (1984) Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 81:4510\u20134514","journal-title":"Proc Natl Acad Sci USA"},{"key":"308_CR32","first-page":"325","volume-title":"Fields virology","author":"BE Gewurz","year":"2022","unstructured":"Gewurz BE, Longnecker RM, Cohen JI (2022) Epstein-Barr virus. In: Howley PM, Knipe DM, Damania BA, Cohen JI (eds) Fields virology, 7th edn. Wolters Kluwer, Philadelphia, pp 325\u2013388","edition":"7"},{"key":"308_CR33","first-page":"171","volume":"84","author":"SY Gu","year":"1995","unstructured":"Gu SY, Huang TM, Ruan L, Miao YH, Lu H, Chu CM, Motz M, Wolf H (1995) First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 84:171\u2013177","journal-title":"Dev Biol Stand"},{"issue":"23","key":"308_CR34","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.vaccine.2016.04.012","volume":"34","author":"DS Heeke","year":"2016","unstructured":"Heeke DS, Lin R, Rao E, Woo JC, McCarthy MP, Marshall JD (2016) Identification of GLA\/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits. Vaccine 34(23):2562\u20132569","journal-title":"Vaccine"},{"issue":"7","key":"308_CR35","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1084\/jem.20011692","volume":"195","author":"AD Hislop","year":"2002","unstructured":"Hislop AD, Annels NE, Gudgeon NH et al (2002) Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 195(7):893\u2013905","journal-title":"J Exp Med"},{"key":"308_CR36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","volume":"25","author":"AD Hislop","year":"2007","unstructured":"Hislop AD, Taylor GS, Sauce D et al (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25:587\u2013617","journal-title":"Annu Rev Immunol"},{"key":"308_CR37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.587078","volume":"11","author":"G Houen","year":"2020","unstructured":"Houen G, Trier NH (2020) Epstein-Barr virus and systemic autoimmune diseases. Front Immunol 11:587380","journal-title":"Front Immunol"},{"issue":"6","key":"308_CR38","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","volume":"73","author":"EP Hui","year":"2013","unstructured":"Hui EP, Taylor GS, Jia H et al (2013) Phase I trial of recombinant modified vaccinia Ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res 73(6):1676\u20131688","journal-title":"Cancer Res"},{"issue":"7\u20138","key":"308_CR39","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0264-410X(98)00248-5","volume":"17","author":"WT Jackman","year":"1999","unstructured":"Jackman WT, Mann KA, Hoffmann HJ, Spaete RR (1999) Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine 17(7\u20138):660\u2013668","journal-title":"Vaccine"},{"issue":"5","key":"308_CR40","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo M, Bu W, Joyce MG, Meng G, Whittle JR, Baxa U, Yamamoto T, Narpala S, Todd JP, Rao SS, McDermott AB, Koup RA, Rossmann MG, Mascola JR, Graham BS, Cohen JI, Nabel GJ (2015) Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site. Cell 162(5):1090\u20131100","journal-title":"Cell"},{"issue":"6","key":"308_CR41","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1021\/acs.nanolett.0c04687","volume":"21","author":"YF Kang","year":"2021","unstructured":"Kang YF, Zhang X, Yu XH, Zheng Q, Liu Z, Li JP, Sun C, Kong XW, Zhu QY, Chen HW, Huang Y, Xu M, Zhong Q, Zeng YX, Zeng MS (2021) Immunization with a self-assembled nanoparticle vaccine elicits potent neutralizing antibody responses against EBV infection. Nano Lett 21(6):2476\u20132486","journal-title":"Nano Lett"},{"key":"308_CR42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev.micro.54.1.19","volume":"54","author":"R Khanna","year":"2000","unstructured":"Khanna R, Burrows SR (2000) Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Ann Rev Microbiol 54:19\u201348","journal-title":"Ann Rev Microbiol"},{"issue":"1","key":"308_CR43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1084\/jem.176.1.169","volume":"176","author":"R Khanna","year":"1992","unstructured":"Khanna R, Burrows S, Kurilla M et al (1992) Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 176(1):169\u2013176","journal-title":"J Exp Med"},{"issue":"6","key":"308_CR44","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1471-4914(01)02002-0","volume":"7","author":"R Khanna","year":"2001","unstructured":"Khanna R, Tellam J, Duraiswamy J et al (2001) Immunotherapeutic strategies for EBV-associated malignancies. Trends Mol Med 7(6):270\u2013276","journal-title":"Trends Mol Med"},{"issue":"3","key":"308_CR45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/ncponc0107","volume":"2","author":"R Khanna","year":"2005","unstructured":"Khanna R, Moss D, Gandhi M (2005) Technology insight: applications of emerging immunotherapeutic strategies for Epstein\u2013Barr virus-associated malignancies. Nat Clin Pract Oncol 2(3):138\u2013149","journal-title":"Nat Clin Pract Oncol"},{"key":"308_CR46","doi-asserted-by":"crossref","first-page":"9216","DOI":"10.1128\/JVI.00575-07","volume":"81","author":"AN Kirschner","year":"2007","unstructured":"Kirschner AN, Lowrey AS, Longnecker R, Jardetzky TS (2007) Binding-site interactions between Epstein-Barr virus fusion proteins gp42 and gH\/gL reveal a peptide that inhibits both epithelial and B-cell membrane fusion. J Virol 81:9216\u20139229","journal-title":"J Virol"},{"issue":"9","key":"308_CR47","volume":"96","author":"XW Kong","year":"2022","unstructured":"Kong XW, Zhang X, Bu GL, Xu HQ, Kang YF, Sun C, Zhu QY, Ma RB, Liu Z, Zeng YX, Zeng MS, Hu ZL (2022) Vesicular stomatitis virus-based Epstein-Barr virus vaccines elicit strong protective immune responses. J Virol 96(9):e0033622","journal-title":"J Virol"},{"issue":"3","key":"308_CR48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0b013e31828bd87b","volume":"36","author":"F Li","year":"2013","unstructured":"Li F, Song D, Lu Y et al (2013) Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy. J Immunother 36(3):208\u2013214","journal-title":"J Immunother"},{"issue":"10446","key":"308_CR49","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(24)01082-1","volume":"403","author":"P Li","year":"2024","unstructured":"Li P, Meng Z, Zhou Z et al (2024) Therapeutic vaccines for Epstein-Barr virus: a way forward. Lancet 403(10446):2779\u20132780","journal-title":"Lancet"},{"issue":"23","key":"308_CR50","first-page":"6952","volume":"62","author":"CL Lin","year":"2002","unstructured":"Lin CL, Lo WF, Lee TH et al (2002) Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 62(23):6952\u20136958","journal-title":"Cancer Res"},{"issue":"4","key":"308_CR51","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/cmi.2015.29","volume":"13","author":"X Lin","year":"2016","unstructured":"Lin X, Chen S, Xue X et al (2016) Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent. Cell Mol Immunol 13(4):492\u2013501","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"308_CR52","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/cmi.2009.54","volume":"6","author":"G Liu","year":"2009","unstructured":"Liu G, Yao K, Wang B et al (2009) Immunotherapy of Epstein-Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356-364 epitope fusion protein. Cell Mol Immunol 6(6):423\u2013431","journal-title":"Cell Mol Immunol"},{"issue":"21","key":"308_CR53","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMcp1001116","volume":"362","author":"K Luzuriaga","year":"2010","unstructured":"Luzuriaga K, Sullivan JL (2010) Infectious mononucleosis. N Engl J Med 362(21):1993\u20132000","journal-title":"N Engl J Med"},{"issue":"3","key":"308_CR54","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1473-3099(03)00543-7","volume":"3","author":"KF Macsween","year":"2003","unstructured":"Macsween KF, Crawford DH (2003) Epstein-Barr virus-recent advances. Lancet Infect Dis 3(3):131\u2013140","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"308_CR55","volume":"3","author":"H Malhi","year":"2022","unstructured":"Malhi H, Homad LJ, Wan YH, Poudel B, Fiala B, Borst AJ, Wang JY, Walkey C, Price J, Wall A, Singh S, Moodie Z, Carter L, Handa S, Correnti CE, Stoddard BL, Veesler D, Pancera M, Olson J, King NP, McGuire AT (2022) Immunization with a self-assembling nanoparticle vaccine displaying EBV gH\/gL protects humanized mice against lethal viral challenge. Cell Rep Med 3(6):100658","journal-title":"Cell Rep Med"},{"key":"308_CR56","doi-asserted-by":"crossref","first-page":"17474","DOI":"10.1073\/pnas.0404535101","volume":"101","author":"MP McShane","year":"2004","unstructured":"McShane MP, Longnecker R (2004) Cell-surface expression of a mutated Epstein-Barr virus glycoprotein B allows fusion independent of other viral proteins. Proc Natl Acad Sci USA 101:17474\u201317479","journal-title":"Proc Natl Acad Sci USA"},{"key":"308_CR57","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ijc.2910220604","volume":"22","author":"DJ Moss","year":"1978","unstructured":"Moss DJ, Rickinson AB, Pope JH (1978) Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer 22:662\u2013668","journal-title":"Int J Cancer"},{"key":"308_CR58","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ijc.2910230506","volume":"23","author":"DJ Moss","year":"1979","unstructured":"Moss DJ, Rickinson AB, Pope JH (1979) Long-term T-cell-mediated immunity to Epstein-Barr virus in man. III. Activation of cytotoxic T-cells in virus-infected leukocyte cultures. Int J Cancer 23:618\u2013625","journal-title":"Int J Cancer"},{"issue":"1408","key":"308_CR59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1098\/rstb.2000.0784","volume":"356","author":"DJ Moss","year":"2001","unstructured":"Moss DJ, Burrows SR, Silins SL et al (2001) The immunology of Epstein-Barr virus infection. Philos Trans R Soc Lond Ser B Biol Sci 356(1408):475\u2013488","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"issue":"24","key":"308_CR60","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","volume":"25","author":"M Moutschen","year":"2007","unstructured":"Moutschen M, L\u00e9onard P, Sokal EM, Smets F, Haumont M, Mazzu P, Bollen A, Denamur F, Peeters P, Dubin G, Denis M (2007) Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 25(24):4697\u20134705","journal-title":"Vaccine"},{"issue":"1","key":"308_CR61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1084\/jem.176.1.157","volume":"176","author":"RJ Murray","year":"1992","unstructured":"Murray RJ, Kurilla MG, Brooks JM et al (1992) Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 176(1):157\u2013168","journal-title":"J Exp Med"},{"issue":"5","key":"308_CR62","first-page":"233","volume":"50","author":"D Nathwani","year":"1993","unstructured":"Nathwani D, Wood MJ (1993) Herpesvirus infections in childhood: 1. Br J Hosp Med 50(5):233\u2013241","journal-title":"Br J Hosp Med"},{"issue":"4","key":"308_CR63","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5483\/BMBRep.2016.49.4.260","volume":"49","author":"KW Noh","year":"2016","unstructured":"Noh KW, Park J, Kang MS (2016) Targeted disruption of EBNA1 in EBV-infected cells attenuated cell growth. BMB Rep 49(4):226\u2013231","journal-title":"BMB Rep"},{"issue":"13","key":"308_CR64","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12967-015-0415-2","volume":"6","author":"JG Ogembo","year":"2015","unstructured":"Ogembo JG, Muraswki MR, McGinnes LW, Parcharidou A, Sutiwisesak R, Tison T, Avendano J, Agnani D, Finberg RW, Morrison TG, Fingeroth JD (2015 Feb) A chimeric EBV gp350\/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice. J Transl Med 6(13):50","journal-title":"J Transl Med"},{"issue":"9","key":"308_CR65","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1158\/1535-7163.MCT-08-1176","volume":"8","author":"J Pan","year":"2009","unstructured":"Pan J, Zhang Q, Zhou J et al (2009) Recombinant adeno-associated virus encoding Epstein-Barr virus latent membrane proteins fused with heat shock protein as a potential vaccine for nasopharyngeal carcinoma. Mol Cancer Ther 8(9):2754\u20132761","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"308_CR66","doi-asserted-by":"crossref","first-page":"9137","DOI":"10.1128\/JVI.01293-15","volume":"89","author":"A Panikkar","year":"2015","unstructured":"Panikkar A, Smith C, Hislop A et al (2015) Impaired Epstein-Barr virus-specific neutralizing antibody response during acute infectious mononucleosis is coincident with global B-cell dysfunction. J Virol 89(17):9137\u20139141","journal-title":"J Virol"},{"issue":"11","key":"308_CR67","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458514521888","volume":"20","author":"MP Pender","year":"2014","unstructured":"Pender MP, Csurhes PA, Smith C et al (2014) Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Mult Scler 20(11):1541\u20131544","journal-title":"Mult Scler"},{"key":"308_CR68","doi-asserted-by":"crossref","unstructured":"Pender MP, Csurhes PA, Smith C et al (2018) Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight 3(22)","DOI":"10.1172\/jci.insight.124714"},{"issue":"12","key":"308_CR69","doi-asserted-by":"crossref","first-page":"19255","DOI":"10.18632\/oncotarget.13770","volume":"8","author":"EM Perez","year":"2017","unstructured":"Perez EM, Foley J, Tison T, Silva R, Ogembo JG (2017) Novel Epstein-Barr virus-like particles incorporating gH\/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice. Oncotarget 8(12):19255\u201319273","journal-title":"Oncotarget"},{"issue":"8","key":"308_CR70","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","volume":"88","author":"L Rees","year":"2009","unstructured":"Rees L, Tizard EJ, Morgan AJ, Cubitt WD, Finerty S, Oyewole-Eletu TA, Owen K, Royed C, Stevens SJ, Shroff RC, Tanday MK, Wilson AD, Middeldorp JM, Amlot PL, Steven NM (2009) A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 88(8):1025\u20131029","journal-title":"Transplantation"},{"issue":"3","key":"308_CR71","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3390\/vaccines11030540","volume":"11","author":"N Reguraman","year":"2023","unstructured":"Reguraman N, Hassani A, Philip PS, Pich D, Hammerschmidt W, Khan G (2023) Assessing the efficacy of VLP-Based vaccine against Epstein-Barr virus using a rabbit model. Vaccines (Basel) 11(3):540","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"308_CR72","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.it.2014.01.003","volume":"35","author":"AB Rickinson","year":"2014","unstructured":"Rickinson AB, Long HM, Palendira U et al (2014) Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory. Trends Immunol 35(4):159\u2013169","journal-title":"Trends Immunol"},{"issue":"5","key":"308_CR73","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1172\/JCI125364","volume":"129","author":"J Ruhl","year":"2019","unstructured":"Ruhl J, Citterio C, Engelmann C et al (2019) Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas. J Clin Invest 129(5):2071\u20132087","journal-title":"J Clin Invest"},{"issue":"24","key":"308_CR74","doi-asserted-by":"crossref","first-page":"13105","DOI":"10.1128\/JVI.05598-11","volume":"85","author":"R Ruiss","year":"2011","unstructured":"Ruiss R, Jochum S, Wanner G, Reisbach G, Hammerschmidt W, Zeidler R (2011) A virus-like particle-based Epstein-Barr virus vaccine. J Virol 85(24):13105\u201313113","journal-title":"J Virol"},{"issue":"15","key":"308_CR75","doi-asserted-by":"crossref","first-page":"7749","DOI":"10.1128\/JVI.00108-09","volume":"83","author":"C Shannon-Lowe","year":"2009","unstructured":"Shannon-Lowe C, Adland E, Bell AI et al (2009) Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J Virol 83(15):7749\u20137760","journal-title":"J Virol"},{"key":"308_CR76","doi-asserted-by":"crossref","unstructured":"Shannon-Lowe C, Rickinson AB, Bell AI (2017) Epstein-Barr virus-associated lymphomas. Philos Trans R Soc Lond Ser B Biol Sci 372(1732)","DOI":"10.1098\/rstb.2016.0271"},{"issue":"8","key":"308_CR77","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1248\/cpb.c16-00114","volume":"64","author":"Y Si","year":"2016","unstructured":"Si Y, Deng Z, Lan G et al (2016) The safety and immunological effects of rAd5-EBV-LMP2 vaccine in nasopharyngeal carcinoma patients: a phase i clinical trial and two-year follow-up. Chem Pharm Bull (Tokyo) 64(8):1118\u20131123","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"3","key":"308_CR78","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1444","volume":"12","author":"C Smith","year":"2023","unstructured":"Smith C, Khanna R (2023) Adoptive T-cell therapy targeting Epstein-Barr virus as a treatment for multiple sclerosis. Clin Transl Immunol 12(3):e1444","journal-title":"Clin Transl Immunol"},{"issue":"12","key":"308_CR79","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1128\/JVI.00239-09","volume":"83","author":"C Smith","year":"2009","unstructured":"Smith C, Beagley L, Khanna R (2009a) Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression. J Virol 83(12):6192\u20136198","journal-title":"J Virol"},{"issue":"24","key":"308_CR80","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1182\/blood-2009-02-203687","volume":"113","author":"C Smith","year":"2009","unstructured":"Smith C, Wakisaka N, Crough T et al (2009b) Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation. Blood 113(24):6148\u20136152","journal-title":"Blood"},{"key":"308_CR81","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/0008-5472.CAN-11-3399","volume":"72","author":"C Smith","year":"2012","unstructured":"Smith C, Tsang J, Beagley L et al (2012) Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 72:1116\u20131125","journal-title":"Cancer Res"},{"issue":"12","key":"308_CR82","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal EM, Hoppenbrouwers K, Vandermeulen C, Moutschen M, L\u00e9onard P, Moreels A, Haumont M, Bollen A, Smets F, Denis M (2007) Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 196(12):1749\u20131753","journal-title":"J Infect Dis"},{"issue":"11","key":"308_CR83","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.chom.2023.09.011","volume":"31","author":"C Sun","year":"2023","unstructured":"Sun C, Kang YF, Fang XY, Liu YN, Bu GL, Wang AJ, Li Y, Zhu QY, Zhang H, Xie C, Kong XW, Peng YJ, Lin WJ, Zhou L, Chen XC, Lu ZZ, Xu HQ, Hong DC, Zhang X, Zhong L, Feng GK, Zeng YX, Xu M, Zhong Q, Liu Z, Zeng MS (2023) A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV. Cell Host Microbe 31(11):1882\u20131897.e10","journal-title":"Cell Host Microbe"},{"issue":"19","key":"308_CR84","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","volume":"20","author":"GS Taylor","year":"2014","unstructured":"Taylor GS, Jia H, Harrington K et al (2014) A recombinant modified vaccinia Ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res 20(19):5009\u20135022","journal-title":"Clin Cancer Res"},{"key":"308_CR85","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","volume":"33","author":"GS Taylor","year":"2015","unstructured":"Taylor GS, Long HM, Brooks JM et al (2015) The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol 33:787\u2013821","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"308_CR86","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1084\/jem.20062508","volume":"204","author":"J Tellam","year":"2007","unstructured":"Tellam J, Fogg MH, Rist M et al (2007) Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes. J Exp Med 204(3):525\u2013532","journal-title":"J Exp Med"},{"key":"308_CR87","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/jvi.43.2.730-736.1982","volume":"43","author":"DA Thorley-Lawson","year":"1982","unstructured":"Thorley-Lawson DA, Poodry CA (1982) Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol 43:730\u2013736","journal-title":"J Virol"},{"key":"308_CR88","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nm830","volume":"9","author":"SM Tugizov","year":"2003","unstructured":"Tugizov SM, Berline JW, Palefsky JM (2003) Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med 9:307\u2013314","journal-title":"Nat Med"},{"issue":"3","key":"308_CR89","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00253-015-7027-x","volume":"100","author":"M Wang","year":"2016","unstructured":"Wang M, Jiang S, Han Z, Zhao B, Wang L, Zhou Z, Wang Y (2016) Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus. Appl Microbiol Biotechnol 100(3):1221\u20131230","journal-title":"Appl Microbiol Biotechnol"},{"issue":"8258","key":"308_CR90","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S0140-6736(81)91527-0","volume":"2","author":"HB Warner","year":"1981","unstructured":"Warner HB, Carp RI (1981) Multiple sclerosis and Epstein-Barr virus. Lancet 2(8258):1290","journal-title":"Lancet"},{"issue":"643","key":"308_CR91","doi-asserted-by":"crossref","first-page":"eabf3685","DOI":"10.1126\/scitranslmed.abf3685","volume":"14","author":"CJ Wei","year":"2022","unstructured":"Wei CJ, Bu W, Nguyen LA, Batchelor JD, Kim J, Pittaluga S, Fuller JR, Nguyen H, Chou TH, Cohen JI, Nabel GJ (2022) A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice. Sci Transl Med 14(643):eabf3685","journal-title":"Sci Transl Med"},{"key":"308_CR92","doi-asserted-by":"crossref","unstructured":"Wojtak K, Perales-Puchalt A, Weiner DB (2019) Novel synthetic DNA immunogens targeting latent expressed antigens of Epstein-Barr virus elicit potent cellular responses and inhibit tumor growth. Vaccines (Basel) 7(2)","DOI":"10.3390\/vaccines7020044"},{"key":"308_CR93","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.virol.2007.01.025","volume":"363","author":"L Wu","year":"2007","unstructured":"Wu L, Hutt-Fletcher LM (2007) Point mutations in EBV gH that abrogate or differentially affect B cell and epithelial cell fusion. Virology 363:148\u2013155","journal-title":"Virology"},{"key":"308_CR94","doi-asserted-by":"crossref","unstructured":"Wu Q, Chen K, Xue W, Wang G, Yang Y, Li S, Xia N, Chen Y (2024) An insect cell-derived extracellular vesicle-based gB vaccine elicits robust adaptive immune responses against Epstein-Barr virus. Sci China Life Sci","DOI":"10.1007\/s11427-023-2599-1"},{"issue":"13","key":"308_CR95","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.7150\/thno.42494","volume":"10","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zhao B, Ding M, Song S, Kang Y, Yu Y, Xu M, Xiang T, Gao L, Feng Q, Zhao Q, Zeng MS, Krummenacher C, Zeng YX (2020) A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection. Theranostics 10(13):5704\u20135718","journal-title":"Theranostics"},{"issue":"1","key":"308_CR96","doi-asserted-by":"crossref","first-page":"2412640","DOI":"10.1080\/22221751.2024.2412640","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang X, Chen Y, Wang S, Zhong L, Xiang Z, Zhang X, Zhang S, Zhou X, Zhang W, Zhou Y, Zhang Q, Liang J, Luo Y, Wang Y, Chen L, Ye X, Feng Q, Zeng MS, Liu Y, Zeng YX, Shao Y, Xu M (2024) TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice. Emerg Microbes Infect 13(1):2412640","journal-title":"Emerg Microbes Infect"},{"key":"308_CR97","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3389\/fimmu.2018.00932","volume":"9","author":"B Zhao","year":"2018","unstructured":"Zhao B, Zhang X, Krummenacher C, Song S, Gao L, Zhang H, Xu M, Feng L, Feng Q, Zeng M, Xu Y, Zeng Y (2018) Immunization with Fc-based recombinant Epstein-Barr Virus gp350 elicits potent neutralizing humoral immune response in a BALB\/c mice model. Front Immunol 9:932","journal-title":"Front Immunol"},{"issue":"1","key":"308_CR98","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1038\/s41467-024-49546-w","volume":"15","author":"L Zhong","year":"2024","unstructured":"Zhong L, Zhang W, Liu H, Zhang X, Yang Z, Wen Z, Chen L, Chen H, Luo Y, Chen Y, Feng Q, Zeng MS, Zhao Q, Liu L, Krummenacher C, Zeng YX, Chen Y, Xu M, Zhang X (2024) A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection. Nat Commun 15(1):5310","journal-title":"Nat Commun"}],"container-title":["Current Topics in Microbiology and Immunology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2025_308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T11:36:33Z","timestamp":1753443393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2025_308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":98,"URL":"https:\/\/doi.org\/10.1007\/82_2025_308","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"7 June 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}